Alafia AI, Inc. (“ALAFIA”), a leader in omics computing and precision medicine, is today unveiling an expansion of its high-performance computing (HPC) product line to address the growing demand for…
Adicet Bio, Inc. (Nasdaq: ACET), a clinical-stage biotechnology company focused on developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that clinical biomarker data from…
Oscar Health, Inc. (NYSE: OSCR), a leading healthcare technology company, is expanding its presence in New Jersey by offering a wider range of affordable health insurance plans through the ACA…
In the fast-paced and high-stakes environment of the operating room (OR), precision and protection are critical. That’s why Cardinal Health’s Surgical Drapes and Gowns team focuses on creating products designed…
Elation Health, a clinical-first technology company driving innovation in primary care, today shared the results of its latest survey of 100 primary care physicians (PCPs). The survey provides valuable insights…
Cofactor Genomics, Inc., a clinical-stage company focused on bridging the precision medicine gap through RNA decoding, today announced the validation and launch of OncoPrism®-NSCLC, an RNA-based diagnostic test designed to…
Certinal eSign, a leader in Digital Transaction Management, has strengthened its strategic partnership with Bumrungrad International Hospital, a globally recognized healthcare provider, to revolutionize patient registration and data management. This…
Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company focused on using patients’ own biology to treat rare diseases, presented safety data from its Phase 3 ATTeST (Ataxia-Telangiectasia Trial with…
Neurogene Inc. (Nasdaq: NGNE), a clinical-stage biotechnology company focused on developing genetic medicines for rare neurological diseases, today reported positive interim results from the first four participants in the low-dose…
Oncoinvent ASA, a clinical-stage company developing alpha emitter therapies for solid cancers, today reported interim data from the Phase 1/2a trials of Radspherin® for the treatment of peritoneal carcinomatosis. Recruitment…
Tempus AI, Inc. (NASDAQ: TEM), a leader in applying artificial intelligence to drive advancements in precision medicine and patient care, today announced that nine of its abstracts have been accepted…
Castle Biosciences, Inc. (Nasdaq: CSTL), a leader in developing innovative tests to guide patient care, will present new data on the clinical performance of its DecisionDx®-Melanoma and MyPath® Melanoma tests…